Strides Pharma Science Ltd Q3FY21 consolidated net profit slides to Rs. 37.84 crore
Posted On:
Strides Pharma Science Ltd has reported financial results for the period ended December 31, 2020.
Financial Results (Q3 FY20-21) - QoQ Comparison
The company has reported total income of Rs.845.22 crores during the period ended December 31, 2020 as compared to Rs.806.42 crores during the period ended September 30, 2020.
The company has posted net profit / (loss) of Rs.37.84 crores for the period ended December 31, 2020 as against net profit / (loss) of Rs.80.94 crores for the period ended September 30, 2020.
The company has reported EPS of Rs.4.22 for the period ended December 31, 2020 as compared to Rs.9.03 for the period ended September 30, 2020.
Aditya Puri to Chair the Board of Stelis Biopharma, the proposed demerged Biotech Business of Strides
Posted On: 2021-02-04 01:37:49 (Time Zone: Arizona, USA)
Strides Pharma Science Limited (Strides) today announced that the Board of Directors of the Company have approved in principle the demerger of its biotech business under Stelis Biopharma (Stelis). The demerger is expected to unlock significant value for Strides shareholders.
The Board will form a Committee of Directors to explore various options of value discovery including listing of the business on a standalone basis. The Committee will recommend the proposals to the Audit Committee, Committee of Independent Directors and Board including the Scheme, swap ratio and way forward.
Healthcare stocks were trading in green, with the S&P BSE Healthcare index increasing 423.47 points or 2.01% at 21486.76 at 09:48 IST. Among the components of the S&P BSE Healthcare index, Unichem Laboratories Ltd (up 6.83%), Neuland Laboratories Ltd (up 6.59%),Ajanta Pharma Ltd (up 6.53%),Alembic Ltd (up 6.31%),IOL Chemicals & Pharmaceuticals Ltd (up 5.2%), were the top gainers. Among the other gainers were Wockhardt Ltd (up 4.42%), Dr Reddys Laboratories Ltd (up 4.03%), Suven Life Sciences Ltd (up 3.91%), Take Solutions Ltd (up 3.29%), and Granules India Ltd (up 3.22%). On the other hand, Strides Pharma Science Ltd (down 1.6%), Dr Lal Pathlabs Ltd (down 1.03%), and ERIS Lifesciences Ltd (down 0.52%) turned lower.
Better medicines for children
Children are at most risk of dying from malaria. This is why MMV is committed to developing and facilitating access to antimalarial medicines specifically for young populations.
The COVID-19 pandemic has threatened gains made against malaria in children. MMV is working hard to ensure that antimalarial medicines appropriate for children remain available, while bringing forward new formulations.
Medicines are absorbed and metabolized differently in children and should be adapted for their weight and age. To date, MMV and partners have developed and brought to market nine child-friendly formulations (below). In addition, MMV is working with other organizations as part of the PAMAfrica consortium to develop the first malaria treatment for children under 5kg.